Free Trial

HC Wainwright Estimates Journey Medical FY2027 Earnings

Journey Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright cut its FY2027 EPS estimate for Journey Medical to $0.07 from $0.15, while keeping a Buy rating and $13 price target.
  • Journey Medical’s latest quarter missed expectations: it reported a $0.05-per-share loss versus a projected $0.02 loss, and revenue of $18.97 million versus $20.32 million expected.
  • Analyst views are mixed, with two Buy and two Sell ratings; MarketBeat’s average rating is Hold, with an average price target of $13.
  • MarketBeat previews top five stocks to own in December.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Research analysts at HC Wainwright cut their FY2027 earnings per share estimates for Journey Medical in a research note issued on Friday, November 13th. HC Wainwright analyst B. Folkes now anticipates that the company will earn $0.07 per share for the year, down from their prior estimate of $0.15. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($0.13) per share.

A number of other analysts have also weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Journey Medical in a research note on Thursday, October 15th. B. Riley Financial reaffirmed a "buy" rating and issued a $13.00 target price (down from $15.00) on shares of Journey Medical in a report on Friday. Wall Street Zen downgraded shares of Journey Medical from a "buy" rating to a "hold" rating in a research note on Saturday, October 17th. Finally, Zacks Research downgraded shares of Journey Medical from a "hold" rating to a "strong sell" rating in a research note on Thursday. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $13.00.

Read Our Latest Stock Report on Journey Medical

Journey Medical Stock Performance

Shares of Journey Medical stock opened at $4.33 on Monday. The stock has a market cap of $122.19 million, a price-to-earnings ratio of -24.05 and a beta of 1.14. The firm's 50-day moving average is $5.89 and its 200 day moving average is $6.47. Journey Medical has a 1 year low of $4.00 and a 1 year high of $9.56. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.48 and a quick ratio of 1.34.

Journey Medical (NASDAQ:DERM - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The company had revenue of $18.97 million during the quarter, compared to analysts' expectations of $20.32 million. Journey Medical had a negative return on equity of 16.07% and a negative net margin of 7.34%.

Institutional Trading of Journey Medical

A number of institutional investors and hedge funds have recently modified their holdings of DERM. Jump Financial LLC bought a new position in shares of Journey Medical during the third quarter valued at $81,000. Marshall Wace LLP boosted its position in shares of Journey Medical by 38.9% during the third quarter. Marshall Wace LLP now owns 194,311 shares of the company's stock valued at $1,329,000 after buying an additional 54,468 shares during the last quarter. First Eagle Investment Management LLC purchased a new stake in shares of Journey Medical during the third quarter valued at $3,305,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in shares of Journey Medical during the third quarter valued at $68,000. Finally, Salem Investment Counselors Inc. increased its holdings in Journey Medical by 21.0% in the 3rd quarter. Salem Investment Counselors Inc. now owns 35,319 shares of the company's stock worth $242,000 after buying an additional 6,119 shares in the last quarter. Institutional investors own 7.25% of the company's stock.

Key Stories Impacting Journey Medical

These are some of the DERM stories that stood out recently:

  • Positive Sentiment: Journey Medical’s third-quarter loss narrowed and revenue increased, and a report said shares gained in after-hours trading following the results. Article
  • Neutral Sentiment: B. Riley reaffirmed its “Buy” rating but cut its price target to $13 from $15. The lower target is a cautionary change, though it remains well above the $4.48 reference price cited in the report. Article
  • Negative Sentiment: Quarterly adjusted loss was $0.05 per share, worse than the $0.02 loss analysts expected. Revenue of $18.97 million also missed the $20.32 million consensus, which could weigh on sentiment despite the year-over-year improvement. Earnings report

About Journey Medical

(Get Free Report)

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.

Recommended Stories

Earnings History and Estimates for Journey Medical (NASDAQ:DERM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Journey Medical Right Now?

Before you consider Journey Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.

While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines